Tip

Swipe om te navigeren naar een ander artikel

14-09-2017 | Letter to the Editor | Uitgave 11/2017 Open Access

The first-generation ABSORB BVS: awaiting dissolving outcomes

Tijdschrift:: Netherlands Heart Journal > Uitgave 11/2017

Auteurs:: J. Elias, I. M. van Dongen, J. P. S. Henriques

» Naar de volledige tekst

Belangrijke opmerkingen

Reply to the letter from R. Shah: ‘Very-long-term efficacy of bioresorbable vascular scaffolds’. https://doi.org/10.1007/s12471-017-1041-9.

Without Abstract

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Meer informatie

Elias J, van Dongen IM, Kraak RP, et al. Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: a weighted meta-analysis of seven randomised controlled trials including 5577 patients. Neth Heart J. 2017;25:429–38. CrossRefPubMedPubMedCentral

Gao R. Randomized comparison of everolimus-eluting bioresorbable vascular Scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: 3‑year clinical outcomes from ABSORB China. Presented at: annual EuroPCR conference; May 17, 2017; Paris, France. 2017. https://www.tctmd.com/slide/randomized-comparison everolimus- eluting-bioresorbable-vascular-scaffolds-vs-everolimus. Accessed 10 Aug 2017.

Kozuma K. ABSORB Japan: 3‑year clinical and angiographic results of a randomized trial evaluating the absorb bioresorbable vascular scaffoldvs. metallic drug eluting stent in de novo native coronary artery lesions. Presented at: annual EuroPCR conference; May 17, 2017; Paris, France. 2017. https://www.tctmd.com/slide/absorb-japan-results-3-yearclinical-and-angiographic-results. Accessed 10 Aug 2017.

Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–91. CrossRefPubMed

Titel: The first-generation ABSORB BVS: awaiting dissolving outcomes
Auteurs:: J. Elias
I. M. van Dongen
J. P. S. Henriques
Publicatiedatum: 14-09-2017
DOI: https://doi.org/10.1007/s12471-017-1042-8
Uitgeverij: Bohn Stafleu van Loghum
Tijdschrift: Netherlands Heart Journal
Uitgave 11/2017
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Without Abstract

Onze productaanbevelingen

Netherlands Heart Journal

Andere artikelen Uitgave 11/2017

In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment

Appropriate or inappropriate ICD shock; what is the post-shock rhythm?

The preoperative cardiology consultation: indications and risk modification

Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience

Appropriate or inappropriate ICD shock; what is the post-shock rhythm?

Very-long-term efficacy of bioresorbable vascular scaffolds